Abstract
In spite of affecting the life of millions of people, chronic traumatic brain injury (TBI) has not been hitherto treatable with effective pharmacological tools. This review gives a comprehensive summary of the theoretical data supporting the pharmacological manipulation of the cholinergic system in TBI, pointing out the most urgent targets for further studies. The published clinical evidence of cholinergic treatment in TBI is critically reviewed, with emphasis on modern available cholinergic agents. The lessons from these studies are converted to detailed suggestions for further clinical testing. In addition, the treating clinicians are provided with practical advice, based on personal experience of the cholinergic treatment in over 350 TBI patients. It is concluded that cholinergic agents offer several very promising potentials for the treatment of TBI. However, the final breakthrough requires further well-conducted studies and the potential caveats of the treatment have to be acknowledged.
Keywords: Traumatic brain injury, acetylcholine, acetylcholinesterase inhibitors, drug treatment, review
Current Drug Therapy
Title: Cholinergic Treatment of Traumatic Brain Injury
Volume: 1 Issue: 2
Author(s): Olli Sakari Tenovuo
Affiliation:
Keywords: Traumatic brain injury, acetylcholine, acetylcholinesterase inhibitors, drug treatment, review
Abstract: In spite of affecting the life of millions of people, chronic traumatic brain injury (TBI) has not been hitherto treatable with effective pharmacological tools. This review gives a comprehensive summary of the theoretical data supporting the pharmacological manipulation of the cholinergic system in TBI, pointing out the most urgent targets for further studies. The published clinical evidence of cholinergic treatment in TBI is critically reviewed, with emphasis on modern available cholinergic agents. The lessons from these studies are converted to detailed suggestions for further clinical testing. In addition, the treating clinicians are provided with practical advice, based on personal experience of the cholinergic treatment in over 350 TBI patients. It is concluded that cholinergic agents offer several very promising potentials for the treatment of TBI. However, the final breakthrough requires further well-conducted studies and the potential caveats of the treatment have to be acknowledged.
Export Options
About this article
Cite this article as:
Tenovuo Sakari Olli, Cholinergic Treatment of Traumatic Brain Injury, Current Drug Therapy 2006; 1 (2) . https://dx.doi.org/10.2174/157488506776930932
DOI https://dx.doi.org/10.2174/157488506776930932 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuropharmacological Aspects of Crocus sativus L.: A Review of Preclinical Studies and Ongoing Clinical Research
CNS & Neurological Disorders - Drug Targets Role of Microglia in the Pathogenesis of Sepsis-Associated Encephalopathy
CNS & Neurological Disorders - Drug Targets The Effect of the Antioxidant Drug "U-74389G" on Oophoritis During Ischemia Reperfusion Injury in Rats
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Artery of Percheron Infarction: A Characteristic Pattern of Ischemia and Variable Clinical Presentation: A Literature Review
Current Medical Imaging Caveolin-1 in Stroke Neuropathology and Neuroprotection: A Novel Molecular Therapeutic Target for Ischemic-Related Injury
Current Vascular Pharmacology Thermotropic and Spectroscopic Behavior of Skin: Relationship with Percutaneous Permeation Enhancement
Current Drug Delivery Implications of PEGylation of Carbon Nanotubes for Central Nervous System Bioavailability
CNS & Neurological Disorders - Drug Targets Long-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer’s Disease
Current Alzheimer Research Proteases and Protease-Activated Receptors (PARs): Novel Signals for Pain
Current Topics in Medicinal Chemistry Individual Triptan Selection in Migraine Attack Therapy
Recent Patents on CNS Drug Discovery (Discontinued) Neurodegenerative Diseases and Flavonoids: Special Reference to Kaempferol
CNS & Neurological Disorders - Drug Targets PEDF & Stem Cells: Niche vs. Nurture
Current Drug Delivery The Many Roles of Statins in Ischemic Stroke
Current Neuropharmacology Progress and Promise of Nur77-based Therapeutics for Central Nervous System Disorders
Current Neuropharmacology Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery Mesenchymal Stem Cells in the Treatment of Amyotrophic Lateral Sclerosis
Current Stem Cell Research & Therapy Beneficial Actions of Polyunsaturated Fatty Acids in Cardiovascular Diseases: But, How and Why?
Current Nutrition & Food Science Bradykinin B2 receptors play a neuroprotective role in Hypoxia/reoxygenation injury related to pyroptosis pathway
Current Neurovascular Research Microarray Studies in Understanding the Mechanism of Action of Antiepileptic Drugs
Current Psychopharmacology Pharmacological Intervention of Cyclooxygenase-2 and 5-Lipoxygenase Pathways. Impact on Inflammation and Cancer
Current Pharmaceutical Design